Canaccord Genuity Assumes Stoke Therapeutics (STOK) at Buy

April 26, 2023 5:13 AM EDT Send to a Friend
Canaccord Genuity analyst Sumant Kulkami assumes coverage on Stoke Therapeutics (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login